Pieris has established a proprietary portfolio of unique product opportunities in the immunology-related areas of immuno-oncology and asthma, while also having developed programs in other areas including anemia. Based on the promise of our unique therapeutic approach in immuno-oncology and respiratory disease, we intend to make these two core therapeutic areas of the Company, with each indication now anchored by a major alliance: AstraZeneca in respiratory disease and Servier in immuno-oncology.

Beyond its strategic alliances with AstraZeneca and Servier, Pieris also maintains multi-program R&D collaborations with Roche, Daiichi Sankyo and Sanofi to bring its proprietary Anticalin-based therapeutics to patients in a variety of indications. To maximize the value of our pipeline, we are continuing to explore new partnerships to support the development and commercialization of the technology.  As part of the company’s ongoing transformation into an immunology-focused organization, it entered into a Japanese partnership for its anemia program, PRS-080, and will explore out-licensing opportunities in other territories following the completion of an ongoing Phase IIa study for this program.

Immuno-Oncology

View Programs »
Candidate Targets Indication Partner Our Commercial
Rights
Discovery Preclinical IND-
enabling
Phase I Phase Ib/IIa
PRS-343 4-1BB/HER2 Bispecific Immuno-Oncology Worldwide
Discovery Phase completed
Pre-Clinical Phase completed
IND-enabling Phase in progress
Phase 1 not started
Phase 2 not started
PRS-342 4-1BB/GPC3 Bispecific Immuno-Oncology Worldwide
Discovery Phase completed
Pre-Clinical Phase in progress
IND-enabling Phase not started
Phase 1 not started
Phase 2 not started
PRS-300s n.d. Immuno-Oncology Worldwide
Discovery Phase in progress
Pre-Clinical Phase not started
IND-enabling Phase not started
Phase 1 not started
Phase 2 not started
PRS-332 PD-1/n.d. Bispecific Immuno-Oncology U.S.
Discovery Phase completed
Pre-Clinical Phase in progress
IND-enabling Phase not started
Phase 1 not started
Phase 2 not started
Servier 4 Programs n.d./n.d. Bispecific Immuno-Oncology U.S. for 2 bispecifics
Discovery Phase completed
Pre-Clinical Phase not started
IND-enabling Phase not started
Phase 1 not started
Phase 2 not started
Roche n.d. Immuno-Oncology Milestones & Royalties
Discovery Phase in progress
Pre-Clinical Phase not started
IND-enabling Phase not started
Phase 1 not started
Phase 2 not started

Respiratory

View Programs »
Candidate Targets Indication Partner Our Commercial
Rights
Discovery Preclinical IND-
enabling
Phase I Phase Ib/IIa
PRS-060 IL4Ra Asthma U.S. Co-commercialization
Discovery Phase completed
Pre-Clinical Phase completed
IND-enabling Phase in progress
Phase 1 not started
Phase 2 not started
AstraZeneca 4 Programs n.d. Respiratory Diseases U.S. Co-commercialization for 2 targets
Discovery Phase in progress
Pre-Clinical Phase not started
IND-enabling Phase not started
Phase 1 not started
Phase 2 not started

Anemia and Other Disease Areas

View Programs »
Candidate Targets Indication Partner Our Commercial
Rights
Discovery Preclinical IND-
enabling
Phase I Phase Ib/IIa
PRS-080 Hepcidin Anemia Major Markets Ex-Japan
Discovery Phase completed
Pre-Clinical Phase completed
IND-enabling Phase completed
Phase 1 completed
Phase 2 in progress
Daiichi Sankyo n.d. n.d. Milestones & Royalties
Discovery Phase completed
Pre-Clinical Phase completed
IND-enabling Phase in progress
Phase 1 not started
Phase 2 not started
Sanofi P. aeruginosa Infectious Disease Milestones & Royalties
Discovery Phase completed
Pre-Clinical Phase completed
IND-enabling Phase in progress
Phase 1 not started
Phase 2 not started
PRS-110 cMet Oncology Major Markets
Discovery Phase completed
Pre-Clinical Phase in progress
IND-enabling Phase not started
Phase 1 not started
Phase 2 not started